Overview
Rapid changes in influenza antiviral target proteins due to antigenic drift result in the cloaking of the influenza virus from the immune system of vaccinated hosts. Hence, annual formulation updates for influenza vaccines and related antibody therapies are required to preserve immune recognition against different influenza subtypes. Rapid development and thorough characterization of antibody vaccine candidates for influenza viral antigens are essential for treating and preventing potential outbreaks.
Here, Nicoya’s Alto™ digital SPR is used across multiple stages of development including crude library screening, quantitation in serum, epitope binning and kinetics to characterize antibody candidates against Influenza A H5N1 Hemagglutinin (HA).
